<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429895</url>
  </required_header>
  <id_info>
    <org_study_id>M14-198</org_study_id>
    <secondary_id>2014‐005527‐27</secondary_id>
    <nct_id>NCT02429895</nct_id>
  </id_info>
  <brief_title>A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic
      Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled
      Trial (RCT).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Internal business decision
  </why_stopped>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR) 20 response rate by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR) 50 response rate by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR) 70 response rate by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in American College of Rheumatology (ACR) the individual component by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Disease Activity Score DAS28 [hsCRP] by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determine by disease activity score using 28 joint counts (DAS28) and high-sensitivity C-reactive protein (hsCRP) lab test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Psoriatic Disease Activity Score (PASDAS) by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>PASDAS determined by tender or swollen joint counts, patient reported outcome and hsCRP lab test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Psoriasis Area and Severity Index (PASI) by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by scores for the amount and severity of a patient's psoriasis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Psoriasis Target Lesion Score by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by plaque erythema, plaque scaling and plaque thickness scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Dactylitis Assessment by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by presence of dactylitis, swelling, and tenderness in each digit of both hands and both feet.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Enthesitis Sites Comprising the Total Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by the presence and severity of enthesitis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Self-Assessment of Psoriasis Symptoms (SAPS) by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Determined by scores given by patients regarding the severity of their psoriatic symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin biopsy/biomarkers</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Optional samples to assess changes related on disease activity/prognosis of psoriatic arthritis (PsA), autoimmunity/inflammation, and/or response to anti-PsA medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the quality of life, function and work as measured by the Short-Form Health Survey Version 2.0 (SF36v2) by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the quality of life, function and work as measured by Bath AS Disease Activity Index (BASDAI) by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the quality of life, function and work as measured by the Fatigue Numeric Rating Scale by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the quality of life, function and work as measured by the Sleep Quality Scale by visit</measure>
    <time_frame>From Week 0 to Week 24</time_frame>
    <description>Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>All subjects (open-label extension)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will start treatment with ABT-122</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-122</intervention_name>
    <description>Injection</description>
    <arm_group_label>All subjects (open-label extension)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who have completed preceding Study M14-197 (ABT-122) RCT study and have not
             developed any discontinuation criteria of Study M14-197.

          2. If female, subject must meet one of the following criteria:

               -  Postmenopausal (defined as no menses for at least 1 year).

               -  Surgically sterile (bilateral oophorectomy or hysterectomy)

             If subject does not meet one of the above two categories, subject must use one of the
             following methods of birth control, from the time of the first dose of study drug
             until 150 days after the last dose of study drug:

               -  Combined (estrogen and progestogen containing) hormonal contraception associated
                  with inhibition of ovulation started at least 2 months prior to the first dose of
                  study drug: oral, intravaginal or transdermal

               -  Progestogen-only hormonal contraception associated with inhibition of ovulation
                  started at least two months prior to randomization: oral, injectable, or
                  implantable

               -  Intrauterine device (IUD)

               -  Intrauterine hormone-releasing system (IUS)

               -  Bilateral tubal occlusion/ligation

               -  Be with a vasectomized partner (procedure at least 6 months earlier, the
                  vasectomized male partner should be your sole partner)

               -  Sexual abstinence (refraining from heterosexual intercourse during the entire
                  study period)

          3. If male, subject must be surgically sterile (have had a vasectomy more than 6 months
             prior to Screening) or must be practicing at least 1 of the following methods of birth
             control from the time of the first dose of study drug until 150 days post last dose of
             study drug:

               -  Subject using condom and female partner(s) using an intrauterine device (IUD);

               -  Subject using condom and female partner(s) using hormonal contraceptives (oral,
                  vaginal, parenteral or transdermal);

               -  Subject using condom and female partner(s) using double-barrier method
                  (contraceptive sponge; diaphragm or vaginal ring with spermicidal jellies,
                  creams, or spermicide);

               -  Total abstinence from sexual intercourse as the preferred lifestyle of the
                  subject; periodic abstinence is not acceptable.

               -  Subject must also agree to not donate sperm starting on the first day of study
                  drug administration until 150 days after the last dose of study drug.

          4. Subjects must voluntarily sign and date an informed consent, approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the
             initiation of any study-specific procedures.

          5. Subject is judged to be in good health as determined by the Investigator.

        Exclusion Criteria:

          1. Pregnant or breastfeeding or plans to become pregnant during study participation.

          2. Ongoing infections at Day 1 (Week 0) that have NOT been successfully treated within 14
             days.

          3. Anticipated requirement or receipt of any live vaccine during study participation
             including up to 120 days after the last dose of study drug.

          4. Current enrollment in another investigational study; with the exception of Study
             M14-197, which is required.

          5. Consideration by the Investigator, for any reason, that the subject is an unsuitable
             candidate to continue to receive ABT-122.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heikki T Mansikka, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138922</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138925</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138926</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138927</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138928</name>
      <address>
        <city>Sofia</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138930</name>
      <address>
        <city>Sofia</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138929</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138934</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138933</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138932</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141365</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138953</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138959</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138983</name>
      <address>
        <city>Adazi</city>
        <zip>LV-2164</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138985</name>
      <address>
        <city>Riga</city>
        <zip>LV-1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138982</name>
      <address>
        <city>Riga</city>
        <zip>LV1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138984</name>
      <address>
        <city>Valmiera</city>
        <zip>LV-4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138986</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138988</name>
      <address>
        <city>Nelson</city>
        <zip>7010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138987</name>
      <address>
        <city>Newtown, Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139000</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139012</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138999</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139007</name>
      <address>
        <city>Katowice</city>
        <zip>40-748</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139006</name>
      <address>
        <city>Krakow</city>
        <zip>31-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139005</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139026</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139004</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139001</name>
      <address>
        <city>Stalowa Wola</city>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139011</name>
      <address>
        <city>Szczecin</city>
        <zip>70-332</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139003</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139010</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139013</name>
      <address>
        <city>Bucuresti</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139016</name>
      <address>
        <city>Targu-Mures, Jud. Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139022</name>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139020</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methotrexate</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

